(11/4, Fiore) reported, "A vasopressin receptor antagonist slowed both the rise in kidney volume and the decline in kidney function in patients with autosomal dominant polycystic kidney disease (ADPKD)," according to research presented at Kidney Week and published online in the New England Journal of Medicine. "In a phase III trial, gains in total kidney volume were higher for patients treated with placebo compared with those on tolvaptan (5.5% per year versus 2.8% per year)," researchers reported. "However, tolvaptan treatment was associated with a higher discontinuation rate because of certain adverse events compared with placebo, the authors warned." An accompanying editorial "noted that there were no effects on the 'worsening trajectories of hypertension and albuminuria.'"
No comments:
Post a Comment